Signature Mapping TBDx Tuberculosis Diagnostics Solution to Be Deployed in Remote Intensive Case Finding Project
September 14 2011 - 11:37AM
Marketwired
Signature Mapping Medical Sciences, Inc. a subsidiary of Applied
Visual Sciences, Inc. (OTCBB: APVS) announces today through its
on-going partnership with the Aurum Institute for Health Research
in South Africa, Signature Mapping Medical Sciences, Inc. will be
deploying the TBDx automated slide management visualization
screening solution as a component of an innovative mobile
tuberculosis (TB) case finding project. The mobile unit aims to
deliver a comprehensive tuberculosis detection and treatment
capability to remote villages in South Africa.
The mobile TB case finding project has received approval from a
governmental funding agency, with funds available for the
acquisition of TBDx, upon approval of the agency's fiscal year
budget. Funding will allow for the creation and deployment of up to
4 mobile units. The units will contain the latest and most
sophisticated technologies for the detection of tuberculosis. TBDx
will work alongside digital X-rays and GeneXpert, the molecular
diagnostic system, as the Aurum Institute seeks to expand effective
TB case finding closer to the point of care using the combined
technologies.
"Until we can bring effective diagnosis closer to the people
most in need, the devastating effects of TB will continue to plague
our communities," noted Dr. Dave Clark, Deputy CEO of the Aurum
Institute. "We see these mobile units, outfitted with TBDx and
other technologies, playing an innovative role in collecting sputum
samples, visualizing slides, screening patients, and assisting in
case diagnosis, without extensive deployment of scarce laboratory
and radiology staff resources."
"We could not be more pleased to be participating in this
vitally important project with Aurum," commented Bill Donovan,
President and Chief Operating Officer of Signature Mapping Medical
Sciences. "Providing innovative, cutting-edge technologies to the
poorest and most heavily TB burdened areas of the country will
allow more South African citizens to be screened and treated. Mass
population screening in those areas could potentially slow the
spread of the disease and have a lasting impact on the growth of
the disease."
About TBDx The SM TBDx solution combines Applied Visual
Sciences' highly sensitive and specific image analysis software
with an automated slide loader capable of processing 200 slides
without human intervention, a bar code reader, an automated
microscope stage navigator to process the slide through the capture
of 100 fields of view (FOV), and an auto-focus camera to digitally
capture each FOV. SM TBDx Manages and synchronizes the hardware
components for hands-free slide acquisition and TB detection
analysis. A video of the TBDx automated solution is available at
the following link: http://www.youtube.com/watch?v=Wn6k5YxhFjU
About Aurum Institute The Aurum Institute is an internationally
recognized African research and health systems organization,
dedicated to making a major impact in the fight against TB and HIV.
For more information go to www.auruminstitute.org
About Applied Visual Sciences, Inc. Applied Visual Sciences,
Inc. is the holding company and IT development organization for
subsidiaries specializing in high-performance imaging analysis
technologies and advanced analytics for automated recognition of
targets of interest. Applied Visual Sciences' subsidiaries include
Guardian Technologies International, Inc., a homeland
security/defense technology entity, and Signature Mapping Medical
Sciences, Inc., a healthcare technology entity. The company is
quoted on the OTC Bulletin Board under the symbol APVS.
Safe Harbor statement under the Private Securities Litigation
Reform Act of 1995: Statements in this news release looking forward
in time involve risks and uncertainties, including the risks
associated with the effect of changing economic conditions, capital
raising activities, trends in the markets, variations in the
company's cash flow, competition, business development efforts,
technology availability and cost of materials and other risk
factors. Factors that could cause actual results to differ
materially are discussed in the Company's most recent filings with
the Securities and Exchange Commission.
Add to Digg Bookmark with del.icio.us Add to Newsvine
CONTACT: For Applied Visual Sciences: William Donovan +1
703-464-5495 For Signature Mapping Medical Sciences Sean
Kennedy +1 703-464-5495 For Media: Julie Shepherd of
Accentuate PR Email Contact +1 815-479-1833
Applied Visual Sciences (CE) (USOTC:APVS)
Historical Stock Chart
From Jan 2025 to Feb 2025
Applied Visual Sciences (CE) (USOTC:APVS)
Historical Stock Chart
From Feb 2024 to Feb 2025